Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Exclusion Criteria

• •Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
• •History of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy
• •Known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression
• •Leptomeningeal disease
• •Active autoimmune diseases requiring systemic treatment within the past 2 years
• •Previous systemic anti-tumor therapy for locally advanced, unresectable, or metastatic NSCLC
• •Previous treatment with immunotherapy (exception is (neo)adjuvant anti-PD-(L)1), ADCs containing MMAE payload, systemic anti-angiogenic therapy, or prior radiotherapy to the lung within 6 months of first dose of study intervention